VICPOTCPharmaceutical PreparationsFiscal year ends December 31

Vicapsys Life Sciences, Inc.

Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Jan 10, 2025

$0.40+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $13.73M
P/E (TTM): –
Dividend yield: –

Vicapsys Life Sciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Research & Development	0.02	0.01	0.02	0.10	0.10
General & Administrative	0.10	0.06	0.04	0.05	0.05
Operating Expenses	1.05	0.98	0.34	0.77	1.03
Operating Income	-1.05	-0.98	-0.34	-0.77	–
Interest Expense	0.02	–	–	–	–
Income from Equity Investments	–	–	0.10	–	–
Other Non-Operating Income	-0.14	–	0.10	–	–
Asset Impairment Charges	–	0.34	–	–	–
Pretax Income	-1.18	-0.98	-0.24	-0.77	-1.03
Income from Continuing Operations	–	–	–	-0.77	-1.03
Income from Discontinued Operations	–	–	–	–	-0.38
Net Income	-1.18	-0.98	-0.24	-0.77	-1.41
Net Income to Common	-1.18	-0.99	-0.24	-0.77	-1.57
EPS (Basic)(per share)	-0.03	-0.03	-0.01	-0.04	-0.13
EPS (Diluted)(per share)	-0.03	-0.03	-0.01	-0.04	-0.13
Shares Outstanding (Basic, Weighted)(shares)	35	31	18	17	11
Shares Outstanding (Diluted, Weighted)(shares)	35	31	18	17	11

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2024

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2023: 82.1%

Financial strength

Current ratio: 0.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –